Hong Kong, 25 June 2026
Opharmic Technology (HK) Limited today announced the formation of its Scientific Advisory Board (SAB), a distinguished group of five internationally recognized retinal specialists spanning the United States, United Kingdom, Australia, Singapore, and Switzerland. This broad geographic representation strengthens the company’s global clinical and scientific perspective as it advances its non-invasive ultrasound platforms toward pivotal milestones.
The SAB members (presented in alphabetical order) bring unparalleled expertise in retinal disease management, clinical trial design, and translational ophthalmology research:
The SAB will provide high-level strategic guidance on clinical development programs, study protocols, and regulatory strategy for Opharmic’s core platform - MeticTouch® - offering a non-invasive ultrasound approach in ocular drug delivery.
“Establishing this SAB with such eminent retinal leaders across key regions is a significant step in our clinical advancement,” said Dr. Langston Suen, CEO of Opharmic Technology. “Their collective expertise will be instrumental in ensuring the highest scientific and clinical standards as we prepare for First-in-Human studies and pursue our mission to deliver transformative, patient-friendly solutions in ophthalmology.”
This announcement reinforces Opharmic’s commitment to rigorous, globally informed development, as the company continues to build momentum toward regulatory and commercial milestones in non-invasive ultrasound innovation.
Opharmic Technology